HBV相关肝细胞癌患者血清UCA1、WRAP53表达水平及其临床意义

摘要/Abstract

摘要： 目的探究乙型肝炎病毒(HBV)相关肝细胞癌患者血清尿路上皮癌相关1(UCA1)和含TP53反义的WD重复序列(WRAP53)水平与肝癌的关系。方法选取2022年6月至2024年3月于乐至县人民医院肿瘤内科接受治疗的HBV相关肝细胞癌患者82例作为观察组,选择同期慢性HBV感染者80例作为对照组。实时荧光定量PCR测定患者血清UCA1和WRAP53水平,应用二元logistic回归模型分析慢性HBV感染者肝癌发生的危险因素。采用受试者工作特征(ROC)曲线及曲线下面积(AUC)评估UCA1和WRAP53对HBV相关肝细胞癌的诊断效能。结果观察组血清UCA1和WRAP53的表达水平分别为(2.42±0.72)和(3.16±1.07),高于对照组的(1.25±0.37)和(1.18±0.31),差异有统计学意义(t=13.054、16.079,均P<0.05)。Logistic回归分析表明,UCA1和WRAP53水平升高是慢性HBV感染者肝癌发生的独立危险因素。ROC曲线分析显示,UCA1和WRAP53诊断慢性HBV感染者肝癌发生的灵敏度分别为84.1%和90.2%;特异度分别为88.7%和96.3%;AUC分别为0.921和0.930,显示了两者在诊断慢性HBV感染者肝癌发生的高准确性。而当UCA1和WRAP53联合预测时,灵敏度和特异度分别为93.9%和98.8%,AUC值则达到0.980,表明联合检测具有更高的预测效能。结论 HBV相关肝细胞癌患者的血清UCA1和WRAP53水平显著升高,这些标志物可作为HBV相关肝细胞癌的潜在诊断工具,具有较高的诊断价值。

关键词: 乙型肝炎病毒, 肝细胞癌, UCA1, WRAP53, 生物标志物

Abstract: Objective To investigate the relationship between serum urothelial carcinoma-associated 1 (UCA1) and WD repeat-containing antisense to TP53 (WRAP53) levels and hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-related HCC. Methods A total of 82 patients with HBV-related HCC treated at the Oncology Department of Lezhi County People′s Hospital from June 2022 to March 2024 were selected as the observation group, and 80 chronic HBV-infected patients during the same period were selected as the control group. Serum UCA1 and WRAP53 levels were measured by quantitative real-time polymerase chain reaction (PCR). Binary logistic regression analysis of risk factors for HCC occurrence in chronic HBV-infected patients. The diagnostic value of UCA1 and WRAP53 for HBV-related HCC was evaluated by the area under the receiver operating characteristic curve (AUROC). Results The serum UCA1 and WRAP53 expression levels in the observation group were (2.42±0.72) and (3.16±1.07), respectively, which were higher than those in the control group ((1.25±0.37) and (1.18±0.31)). The differences were statistically significant (t=13.054, 16.079, both P<0.05). Logistic regression analysis showed that elevated UCA1 and WRAP53 levels were independent risk factors for HCC in chronic HBV patients. ROC curve analysis showed that the sensitivity and specificity of UCA1 and WRAP53 in diagnosing HCC were 84.1% and 88.7%, and 90.2% and 96.3%, respectively, with AUROC values of 0.921 and 0.930. This indicated a high diagnostic accuracy. When UCA1 and WRAP53 were combined, the sensitivity and specificity were 93.9% and 98.8%, respectively, and the AUROC was 0.980, indicating a higher diagnostic performance. Conclusion The serum levels of UCA1 and WRAP53 in patients with HBV-related HCC were significantly elevated. These biomarkers can serve as potential diagnostic tools for HBV-related HCC, with high diagnostic value.

Key words: Hepatitis B virus, Hepatocellular carcinoma, UCA1, WRAP53, Biomarkers

杨斌, 王勇刚, 曹洪刚, 高建勇. HBV相关肝细胞癌患者血清UCA1、WRAP53表达水平及其临床意义[J]. 肝脏, 2025, 30(7): 943-947.

YANG Bin, WANG Yong-gang, CAO Hong-gang, GAO Jian-yong. Serum UCA1 and WRAP53 expression levels in HBV-related hepatocellular carcinoma patients and their correlation with hepatocellular carcinoma[J]. Chinese Hepatolgy, 2025, 30(7): 943-947.

/ 推荐

参考文献

[1] 全黎莉, 宋海斌, 宋丽良. 肝细胞癌患者脂代谢异常的特征、脂肪酸结合蛋白的表达及其临床意义[J]. 中国现代医学杂志,2023,33(10):89-94.
[2] Zhu R X, Seto W K, Lai C L, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J]. Gut Liver, 2016, 10(3): 332-339.
[3] 王焘, 王文涛. 肝细胞癌免疫治疗的现状及发展[J]. 四川大学学报(医学版),2023,54(3):692-698.
[4] 亚库甫·托合提, 张凯楠, 赵辉, 等. 血清毒蕈碱乙酰胆碱受体m3自身抗体水平对甲胎蛋白阴性肝细胞癌的诊断价值[J]. 中国全科医学,2022,25(17):2110-2114.
[5] 李萌, 刘爽. P53及其相关lncRNA在癌症发生中的作用机制[J]. 国际药学研究杂志,2020,47(8):583-588.
[6] 张振东, 王小平. 长链非编码RNA在消化道癌症中的作用及临床应用[J]. 浙江大学学报(医学版),2023,52(4):451-459.
[7] 郑斌, 王宇. 长链非编码RNA UCA1在消化系统肿瘤中的研究进展[J]. 中国肿瘤,2018,27(3):209-213.
[8] 杨金鹏, 张永博. LncRNA UCA1调控消化系统肿瘤发病机制的研究进展[J]. 中国中西医结合消化杂志,2023,31(8):643-648.
[9] Gadelha R B, Machado C B, Pessoa F M C P, et al. The role of WRAP53 in cell homeostasis and carcinogenesis onset[J]. Curr Issues Mol Biol, 2022, 44(11): 5498-5515.
[10] Zhu Y, Sun W, Jiang X, et al. Differential effects of WRAP53 transcript variants on non-small cell lung cancer cell behaviors[J]. Plos one, 2023, 18(1): e0281132.
[11] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤防治研究,2022,49(3):251-276.
[12] Shiels M S, Engels E A, Yanik E L, et al. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013[J]. Cancer, 2019, 125(15): 2621-2630.
[13] Alshuwaykh O, Daugherty T, Cheung A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy[J]. Hepatol Commun, 2022, 6(11): 3052-3061.
[14] D′souza S, Lau K C K, Coffin C S, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma[J]. World J Gastroentero, 2020, 26(38): 5759-5783.
[15] Mason W S, Jilbert A R, Litwin S. Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver[J]. Viruses, 2021, 13(2): 210.
[16] Pelizzaro F, Vitale A, Sartori A, et al. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients[J]. Cancers, 2021, 13(4): 897.
[17] Parikh N D, Mehta A S, Singal A G, et al. Biomarkers for the early detection of hepatocellular carcinoma[J]. CEBP, 2020, 29(12): 2495-2503.
[18] Ahn J C, Teng P C, Chen P J, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73(1): 422-436.
[19] Hanif H, Ali M J, Susheela A T, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma[J]. World J Gastroenterol, 2022, 28(2): 216-229.
[20] Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma[J]. J Cancer Res Clin, 2020, 146(10): 2439-2446.
[21] Xu Y, Guo Q, Wei L. The emerging influences of alpha-fetoprotein in the tumorigenesis and progression of hepatocellular carcinoma[J]. Cancers, 2021, 13(20): 5096.
[22] Pouladi N, Abdolahi S, Farajzadeh D, et al. Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer[J]. PLoS One, 2019, 14(8): e0220727.
[23] Abdelmoety A A, Elhassafy M Y, Said R S O, et al. The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: a single-center case-control study[J]. JCEH, 2023, 9(2): 129-137.
[24] Zhou Y, Li Y, Wang N, et al. UPF1 inhibits the hepatocellular carcinoma progression by targeting long non-coding RNA UCA1[J]. Scientific Reports, 2019, 9(1): 6652.
[25] Huang G, Li L, Liang C, et al. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR‐138‐5p and activation of AKT/mTOR signaling pathway[J]. Pharmacol Res Perspe, 2021, 9(1): e00720.
[26] Kamel M M, Matboli M, Sallam M, et al. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma[J]. Transl Res, 2016, 100(168): 134-145.